A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities
- 28 March 2011
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 71 (15), 1656-1667
- https://doi.org/10.1002/pros.21382
Abstract
BACKGROUND The diversity and complexity of the human androgen receptor (AR) splicing variants are well appreciated but not fully understood. The goal of this study is to generate a comprehensive expression signature of AR variants in castration‐resistant prostate cancer (CRPC), and to address the relative importance of the individual variants in conferring the castration‐resistant phenotype. METHODS A modified RNA amplification method, termed selective linear amplification of sense RNA, was developed to amplify all AR transcripts containing AR exon 3 in CRPC specimens, which were profiled using tiling expression microarrays. Coding sequences for the AR variants were cloned into expression vectors and assessed for their transcriptional activities. Quantitative RT‐PCR was used to determine their in vivo expression patterns in an expanded set of clinical specimens. RESULTS In addition to expression peaks in AR intron 3, a novel AR exon, termed exon 9, was discovered. Exon 9 was spliced into multiple novel AR variants. Different AR splicing variants were functionally distinctive, with some demonstrating constitutive activity while others were conditionally active. Conditionally active AR‐Vs may activate AR signaling depending on the cellular context. Importantly, AR variant functions did not appear to depend on the full‐length AR. CONCLUSIONS This study provided the first unbiased snapshot of the AR variant signature consisting of multiple AR variants with distinctive functional properties, directly in CRPC specimens. Study findings suggest that the aggregate function of multiple AR variants may confer a castration‐resistant phenotype independent of the full‐length AR. Prostate 71:1656–1667, 2011.Keywords
This publication has 26 references indexed in Scilit:
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptorProceedings of the National Academy of Sciences, 2010
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetThe Lancet Oncology, 2009
- The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasetsBioinformatics, 2009
- Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate CancerClinical Cancer Research, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion–Resistant GrowthCancer Research, 2009
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate CancerCancer Research, 2008
- Targeting the androgen receptor pathway in prostate cancerCurrent Opinion in Pharmacology, 2008
- Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implicationsBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expressionGenes & Development, 2006